These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 11457543)

  • 1. Vaccination against bubonic and pneumonic plague.
    Titball RW; Williamson ED
    Vaccine; 2001 Jul; 19(30):4175-84. PubMed ID: 11457543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
    Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral vaccination against plague using Yersinia pseudotuberculosis.
    Demeure CE; Derbise A; Carniel E
    Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plague.
    Williamson ED
    Vaccine; 2009 Nov; 27 Suppl 4():D56-60. PubMed ID: 19837288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yersinia pestis (plague) vaccines.
    Titball RW; Williamson ED
    Expert Opin Biol Ther; 2004 Jun; 4(6):965-73. PubMed ID: 15174978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bubonic and pneumonic plague using plant-derived vaccines.
    Alvarez ML; Cardineau GA
    Biotechnol Adv; 2010; 28(1):184-96. PubMed ID: 19931370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational considerations about development of live attenuated Yersinia pestis vaccines.
    Sun W; Curtiss R
    Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
    Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
    Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice.
    Bozue J; Cote CK; Webster W; Bassett A; Tobery S; Little S; Swietnicki W
    FEMS Microbiol Lett; 2012 Jul; 332(2):113-21. PubMed ID: 22537022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice.
    Alvarez ML; Pinyerd HL; Crisantes JD; Rigano MM; Pinkhasov J; Walmsley AM; Mason HS; Cardineau GA
    Vaccine; 2006 Mar; 24(14):2477-90. PubMed ID: 16442673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual route vaccination for plague with emergency use applications.
    Moore BD; New RRC; Butcher W; Mahood R; Steward J; Bayliss M; MacLeod C; Bogus M; Williamson ED
    Vaccine; 2018 Aug; 36(34):5210-5217. PubMed ID: 30017148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
    Quenee LE; Schneewind O
    Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine.
    Bubeck SS; Dube PH
    Clin Vaccine Immunol; 2007 Sep; 14(9):1235-8. PubMed ID: 17652523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing live vaccines against plague.
    Sun W; Roland KL; Curtiss R
    J Infect Dev Ctries; 2011 Sep; 5(9):614-27. PubMed ID: 21918302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.